CDK2AP1 and prostate cancer: In vitro studies focused on overexpression of CDK2AP1 in prostate cancer cell lines results in a decrease in levels of CDK2 and its kinase activity, leading to an accumulation of cells in the G1 phase and a reduction in cells that are in the S phase of the cell cycle [2].